Four IPOs made it to market this past week, as several small deals delayed (BFRG, INTS, LRE, LSDI). Three companies joined the pipeline, including one filing to raise $100 million. TXO Energy Partners LP (TXO) led the week’s...read more
Genelux, a Phase 3 biotech developing oncolytic viral immunotherapies for solid tumors, raised $15 million by offering 2.5 million shares at $6, the low end of the range of $6 to $7. Genelux is developing a pipeline of oncolytic viral immunotherapies for...read more
Eight companies are currently scheduled to go public in the week ahead, seven of which are eligible for inclusion in our IPO stats. If all seven qualifying deals price, it would be the busiest week for the US IPO market in over a year. The week’s lineup...read more
Renaissance Capital's January IPO Market Update
Following the challenges of the prior year, the 2023 IPO market started off strong with the Renaissance IPO Index climbing 16%, more...read more
US IPO Weekly Recap: Oil and gas producer TXO leads a 4 IPO week
Four IPOs made it to market this past week, as several small deals delayed (BFRG, INTS, LRE, LSDI). Three companies joined the pipeline, including one filing to raise $100 million. TXO Energy Partners LP (TXO) led the week’s...read more
Solid tumor biotech Genelux prices IPO at $6 low end
Genelux, a Phase 3 biotech developing oncolytic viral immunotherapies for solid tumors, raised $15 million by offering 2.5 million shares at $6, the low end of the range of $6 to $7. Genelux is developing a pipeline of oncolytic viral immunotherapies for...read more
US IPO Week Ahead: January closes out with a busy IPO calendar, led by energy company TXO
Eight companies are currently scheduled to go public in the week ahead, seven of which are eligible for inclusion in our IPO stats. If all seven qualifying deals price, it would be the busiest week for the US IPO market in over a year. The week’s lineup...read more